Literature DB >> 34224098

Comparison of clinical outcomes between percutaneous coronary intervention for de novo lesions versus in-stent restenosis lesions.

Mitsuhiro Takeuchi1, Tomotaka Dohi2, Tatsuya Fukase1, Ryota Nishio1, Norihito Takahashi1, Hirohisa Endo1, Shinichiro Doi1, Yoshiteru Kato1, Iwao Okai1, Hiroshi Iwata1, Shinya Okazaki1, Kikuo Isoda1, Katsumi Miyauchi1, Tohru Minamino1,3.   

Abstract

In-stent restenosis (ISR) remains the primary concern after a percutaneous coronary intervention (PCI) and is considered to be associated with worse clinical outcomes. However, comparative data on ISR and de novo lesions are rare. Therefore, we aimed to compare PCI-related clinical outcomes between patients with de novo lesions and those with ISR lesions. We undertook a retrospective analysis of patients who had undergone a PCI between 2013 and 2020. The incidences of major adverse cardiac and cerebrovascular events (MACCE) and all-cause death over a 2-year follow-up period were evaluated. In total, 1538 patients were enrolled and divided into two groups: a de novo lesions group (n = 1258, 81.8%) and an ISR lesions group (n = 280, 18.2%). Patients in the ISR lesions group were significantly older, with a higher prevalence of hypertension, diabetes mellitus, dyslipidemia, and chronic kidney disease than those in the de novo lesions group. Kaplan-Meier curves showed no significant between-group differences in the incidence of MACCE (log-rank, p = 0.93) and all-cause death (p = 0.09). After adjustment for other covariates, PCIs for ISR lesions were not found to be significantly associated with MACCE (hazard ratio [HR], 1.10; 95% confidential interval [CI] 0.49-2.49; p = 0.81) and all-cause death (HR, 0.58; 95% CI 0.26-1.31; p = 0.19). PCIs for ISR lesions were not associated with worse clinical outcomes compared with PCIs for de novo lesions.
© 2021. Japanese Association of Cardiovascular Intervention and Therapeutics.

Entities:  

Keywords:  Coronary artery disease; In-stent restenosis; Percutaneous coronary intervention

Mesh:

Year:  2021        PMID: 34224098     DOI: 10.1007/s12928-021-00792-5

Source DB:  PubMed          Journal:  Cardiovasc Interv Ther        ISSN: 1868-4297


  1 in total

1.  Restenosis of Drug-Eluting Stents: A New Classification System Based on Disease Mechanism to Guide Treatment and State-of-the-Art Review.

Authors:  Evan Shlofmitz; Micaela Iantorno; Ron Waksman
Journal:  Circ Cardiovasc Interv       Date:  2019-07-26       Impact factor: 6.546

  1 in total
  2 in total

1.  Random forest vs. logistic regression: Predicting angiographic in-stent restenosis after second-generation drug-eluting stent implantation.

Authors:  Zhi Jiang; Longhai Tian; Wei Liu; Bo Song; Chao Xue; Tianzong Li; Jin Chen; Fang Wei
Journal:  PLoS One       Date:  2022-05-23       Impact factor: 3.752

Review 2.  Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes.

Authors:  Grzegorz K Jakubiak; Natalia Pawlas; Grzegorz Cieślar; Agata Stanek
Journal:  Int J Environ Res Public Health       Date:  2021-11-15       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.